Yoshitaka Watanabe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yoshitaka Watanabe has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Hirokazu Ikeda
Children's Medical Center Showa Medical University Northern Yokohama Hospital Yokohama Kanagawa Japan
22 shared publications Tsuneki Watanabe
Children's Medical Center Showa University Northern Yokohama Hospital Yokohama Kanagawa Japan
10 shared publications- Tsuneki Watanabe
Children's Medical Center Showa Medical University Northern Yokohama Hospital Yokohama Kanagawa Japan
7 shared publications Yuta Onuki
Children's Medical Center Showa Medical University Northern Yokohama Hospital Yokohama Kanagawa Japan
7 shared publicationsTakahiro Ono
Children's Medical Center Showa Medical University Northern Yokohama Hospital Yokohama Kanagawa Japan
6 shared publicationsMasaki Fuyama
5 shared publications
Latest Publications
- Open Access
- 24 September 2026
- Published by Wiley in Neurourology and Urodynamics
Association Between Toilet Training Timing and Prognosis of Nocturnal Enuresis in Children: A Retrospective Study
Aims: Toilet training (TT) is a critical developmental milestone with potential implications for lower urinary tract function. However, its association with the prognosis of nocturnal enuresis (NE) remains unclear. We aimed to evaluate whether the timing of TT initiation and completion affects 1‐year treatment outcomes in children with NE. Methods: We conducted a retrospective cohort study of 163 children diagnosed with NE between April 2020 and March 2023. Patients were classified into complete response (CR) and non‐CR groups based on 1‐year treatment outcomes. Data on TT timing, constipation, and daytime incontinence (DI) were obtained from medical records and a structured questionnaire. Statistical analyses included the chi‐square test, Mann–Whitney U test, and multivariate logistic regression. Results: The median age of the cohort was 8 years, and 66.9% of the patients were male. TT was initiated before 3 years of age in 67.5% of patients and completed before 4 years of age in 50.9%. Early TT completion was associated with a significantly lower rate of DI; however, no significant association was observed between TT timing and achievement of CR. In multivariate analysis, neither early TT initiation nor early TT completion independently predicted CR. Conclusions: Although early TT may be associated with a reduced prevalence of DI, TT timing was not significantly associated with CR at 1 year in this cohort. Constipation and DI were associated with lower odds of CR in the exploratory multivariable analysis.
- 24 September 2026
- Published by Wiley in Neurourology and Urodynamics
Open AccessAssociation Between Toilet Training Timing and Prognosis of Nocturnal Enuresis in Children: A Retrospective Study
Aims: Toilet training (TT) is a critical developmental milestone with potential implications for lower urinary tract function. However, its association with the prognosis of nocturnal enuresis (NE) remains unclear. We aimed to evaluate whether the timing of TT initiation and completion affects 1‐year treatment outcomes in children with NE. Methods: We conducted a retrospective cohort study of 163 children diagnosed with NE between April 2020 and March 2023. Patients were classified into complete response (CR) and non‐CR groups based on 1‐year treatment outcomes. Data on TT timing, constipation, and daytime incontinence (DI) were obtained from medical records and a structured questionnaire. Statistical analyses included the chi‐square test, Mann–Whitney U test, and multivariate logistic regression. Results: The median age of the cohort was 8 years, and 66.9% of the patients were male. TT was initiated before 3 years of age in 67.5% of patients and completed before 4 years of age in 50.9%. Early TT completion was associated with a significantly lower rate of DI; however, no significant association was observed between TT timing and achievement of CR. In multivariate analysis, neither early TT initiation nor early TT completion independently predicted CR. Conclusions: Although early TT may be associated with a reduced prevalence of DI, TT timing was not significantly associated with CR at 1 year in this cohort. Constipation and DI were associated with lower odds of CR in the exploratory multivariable analysis.
- Open Access
- 1 July 2026
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 69 (8) , 639-645
Association between sodium content of intravenous immunoglobulin and electrolyte changes and clinical course of Kawasaki disease
Background: Intravenous immunoglobulin (IVIG) formulations used to treat Kawasaki disease differ markedly in sodium content; however, the clinical significance of this factor remains unclear.Purpose: Here we investigated whether sodium content influences electrolyte changes and short-term clinical outcomes of Kawasaki disease.Methods: This single-center retrospective cohort study included 744 children with first-episode Kawasaki disease treated with 2-kg IVIG in 2010–2020. The patients were categorized into high-sodium (Glovenin-I or Venilon-I) and low-sodium (Venoglobulin IH) groups. Serum electrolytes, total protein, and immunoglobulin G levels were measured before and after IVIG administration. Outcomes included additional IVIG administration and the presence of coronary artery lesions.Results: Compared to the low-sodium group, the high-sodium group had significantly increased serum sodium (2.9±3.2 mEq/L vs. 1.7±2.7 mEq/L) but significantly decreased serum potassium (-0.13±0.50 mEq/L vs. -0.03±0.49 mEq/L) levels after IVIG therapy. After its administration, hyponatremia occurred more often in the low-sodium group (4.4% vs. 0.3%), whereas hypokalemia occurred more frequently in the high-sodium group (9.9% vs. 5.5%). Total protein, immunoglobulin G, and albumin levels were higher in the low-sodium group. The rates of additional IVIG use and coronary artery lesions did not differ significantly between groups.Conclusion: Our findings demonstrate that the sodium content of IVIG contributes to distinct changes in electrolyte and protein concentrations during the acute phase of Kawasaki disease. However, these biochemical differences were not associated with short-term clinical outcomes. Awareness of formulation-specific profiles may help clinicians interpret laboratory findings appropriately during IVIG therapy.
- 1 July 2026
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 69 (8) , 639-645
Open AccessAssociation between sodium content of intravenous immunoglobulin and electrolyte changes and clinical course of Kawasaki disease
Background: Intravenous immunoglobulin (IVIG) formulations used to treat Kawasaki disease differ markedly in sodium content; however, the clinical significance of this factor remains unclear.Purpose: Here we investigated whether sodium content influences electrolyte changes and short-term clinical outcomes of Kawasaki disease.Methods: This single-center retrospective cohort study included 744 children with first-episode Kawasaki disease treated with 2-kg IVIG in 2010–2020. The patients were categorized into high-sodium (Glovenin-I or Venilon-I) and low-sodium (Venoglobulin IH) groups. Serum electrolytes, total protein, and immunoglobulin G levels were measured before and after IVIG administration. Outcomes included additional IVIG administration and the presence of coronary artery lesions.Results: Compared to the low-sodium group, the high-sodium group had significantly increased serum sodium (2.9±3.2 mEq/L vs. 1.7±2.7 mEq/L) but significantly decreased serum potassium (-0.13±0.50 mEq/L vs. -0.03±0.49 mEq/L) levels after IVIG therapy. After its administration, hyponatremia occurred more often in the low-sodium group (4.4% vs. 0.3%), whereas hypokalemia occurred more frequently in the high-sodium group (9.9% vs. 5.5%). Total protein, immunoglobulin G, and albumin levels were higher in the low-sodium group. The rates of additional IVIG use and coronary artery lesions did not differ significantly between groups.Conclusion: Our findings demonstrate that the sodium content of IVIG contributes to distinct changes in electrolyte and protein concentrations during the acute phase of Kawasaki disease. However, these biochemical differences were not associated with short-term clinical outcomes. Awareness of formulation-specific profiles may help clinicians interpret laboratory findings appropriately during IVIG therapy.
- 1 January 2026
- Published by Wiley in Pediatrics International
- Vol. 68 (1) , e70504
A Rare Case of Kawasaki Disease Complicating Poststreptococcal Acute Glomerulonephritis
- 1 January 2026
- Published by Wiley in Pediatrics International
- Vol. 68 (1) , e70504
A Rare Case of Kawasaki Disease Complicating Poststreptococcal Acute Glomerulonephritis
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Pediatrics
- Vol. 2026 (1)
Kawasaki Disease in a Child With Trisomy 18 Treated With Initial Combination Therapy, Including Cyclosporine
Background: Kawasaki disease is a systemic inflammatory disorder that is frequently encountered in routine pediatric clinical practice. Conversely, trisomy 18 is a chromosomal disorder with a historically poor prognosis. However, recent advances in medical care have improved its survival, with a reported 1‐year survival rate reaching 29%. Despite this improvement, studies describing the clinical course of individuals with trisomy 18 beyond the first year of life remain scarce. Moreover, to our knowledge, cases of Kawasaki disease with trisomy 18 have not been reported. Case Presentation: We report a case of a 3‐year‐11‐month‐old girl with trisomy 18 who presented with persistent fever and rash and, subsequently, fulfilled five of the six principal diagnostic criteria for Kawasaki disease. Because intravenous immunoglobulin resistance was predicted based on the Kobayashi score, initial treatment consisted of intravenous immunoglobulin (2 g/kg), aspirin, and oral cyclosporine concurrent with current Japanese guidelines. Defervescence was achieved without complications, and no adverse events were observed during treatment. No coronary artery abnormalities were observed during the acute phase or at 1‐, 3‐, and 6‐month follow‐up evaluations. Discussion: We present a case of trisomy 18 treated according to Japanese guidelines for Kawasaki disease. Treatment regimen, which included cyclosporine, was safely administered, and the patient experienced a favorable clinical course. To improve the life expectancy of this patient group, it is crucial to accumulate comprehensive natural history, including the efficacy of standard treatments for various pediatric conditions. This will enable timely and appropriate therapeutic interventions.
- 1 January 2026
- Published by Wiley in Case Reports in Pediatrics
- Vol. 2026 (1)
Open AccessKawasaki Disease in a Child With Trisomy 18 Treated With Initial Combination Therapy, Including Cyclosporine
Background: Kawasaki disease is a systemic inflammatory disorder that is frequently encountered in routine pediatric clinical practice. Conversely, trisomy 18 is a chromosomal disorder with a historically poor prognosis. However, recent advances in medical care have improved its survival, with a reported 1‐year survival rate reaching 29%. Despite this improvement, studies describing the clinical course of individuals with trisomy 18 beyond the first year of life remain scarce. Moreover, to our knowledge, cases of Kawasaki disease with trisomy 18 have not been reported. Case Presentation: We report a case of a 3‐year‐11‐month‐old girl with trisomy 18 who presented with persistent fever and rash and, subsequently, fulfilled five of the six principal diagnostic criteria for Kawasaki disease. Because intravenous immunoglobulin resistance was predicted based on the Kobayashi score, initial treatment consisted of intravenous immunoglobulin (2 g/kg), aspirin, and oral cyclosporine concurrent with current Japanese guidelines. Defervescence was achieved without complications, and no adverse events were observed during treatment. No coronary artery abnormalities were observed during the acute phase or at 1‐, 3‐, and 6‐month follow‐up evaluations. Discussion: We present a case of trisomy 18 treated according to Japanese guidelines for Kawasaki disease. Treatment regimen, which included cyclosporine, was safely administered, and the patient experienced a favorable clinical course. To improve the life expectancy of this patient group, it is crucial to accumulate comprehensive natural history, including the efficacy of standard treatments for various pediatric conditions. This will enable timely and appropriate therapeutic interventions.
- Open Access
- 1 November 2025
- Published by AME Publishing Company in Translational Pediatrics
- Vol. 14 (11) , 2955-2967
Safety and efficacy of vibegron in pediatric patients with treatment-resistant nocturnal enuresis: a multicenter retrospective study
Background: Nocturnal enuresis (NE) is a common chronic condition in children. Although enuresis alarms and desmopressin are the first-line treatments recommended by clinical guidelines, 20–40% of affected children demonstrate inadequate response and require additional therapeutic interventions. β3-adrenoceptor agonists are emerging as promising alternatives to anticholinergics, offering a more favorable safety profile with a lower incidence of common side effects. This multicenter retrospective study aimed to evaluate the safety and effectiveness of vibegron in children with treatment-resistant NE (TR-NE) and compare different treatment strategies. Methods: This retrospective observational study was conducted at 12 hospitals affiliated with the Japanese Society on Enuresis and Incontinence. It enrolled children aged 5–18 years who received vibegron (50 mg once daily) for refractory NE between November 2018 and December 2021. The median treatment duration was 245 (interquartile range, 126–484) days. The primary outcome was treatment efficacy, assessed by the change in the number of wet nights over 30 days from baseline to 1 month. Safety was evaluated by monitoring adverse events. Treatment response was defined using the International Children’s Continence Society criteria. Patients were classified into an “add-on” group (vibegron combined with existing therapy) or a “switch” group (transitioned from prior anticholinergics to vibegron). Results: Of the 387 children enrolled, 386 were included for safety analysis and 369 for efficacy evaluation. Four patients (1.0%) experienced mild adverse events that led to the discontinuation of vibegron, and all resolved promptly. Overall, 52.8% achieved a partial or complete response (CR) (≥50% reduction in wet nights), and 17.3% achieved a CR. The add-on group showed significantly greater improvements than the switch group (56.9% vs. 40.1% reduction, Pvs. 11%, P=0.006). Among the subgroups, the alarm addition subgroup showed the greatest reduction in wet nights (71.6%), while triple therapy also achieved high efficacy (61.6%). Conclusions: Vibegron is a safe and effective option for pediatric patients with TR-NE. Add-on strategies—particularly triple therapy—were more effective than monotherapy switching, strengthening the incorporation of vibegron as part of multimodal treatment strategies. Given the retrospective nature of the study, prospective randomized trials are warranted to confirm these findings and optimize the treatment protocols.
- 1 November 2025
- Published by AME Publishing Company in Translational Pediatrics
- Vol. 14 (11) , 2955-2967
Open AccessSafety and efficacy of vibegron in pediatric patients with treatment-resistant nocturnal enuresis: a multicenter retrospective study
Background: Nocturnal enuresis (NE) is a common chronic condition in children. Although enuresis alarms and desmopressin are the first-line treatments recommended by clinical guidelines, 20–40% of affected children demonstrate inadequate response and require additional therapeutic interventions. β3-adrenoceptor agonists are emerging as promising alternatives to anticholinergics, offering a more favorable safety profile with a lower incidence of common side effects. This multicenter retrospective study aimed to evaluate the safety and effectiveness of vibegron in children with treatment-resistant NE (TR-NE) and compare different treatment strategies. Methods: This retrospective observational study was conducted at 12 hospitals affiliated with the Japanese Society on Enuresis and Incontinence. It enrolled children aged 5–18 years who received vibegron (50 mg once daily) for refractory NE between November 2018 and December 2021. The median treatment duration was 245 (interquartile range, 126–484) days. The primary outcome was treatment efficacy, assessed by the change in the number of wet nights over 30 days from baseline to 1 month. Safety was evaluated by monitoring adverse events. Treatment response was defined using the International Children’s Continence Society criteria. Patients were classified into an “add-on” group (vibegron combined with existing therapy) or a “switch” group (transitioned from prior anticholinergics to vibegron). Results: Of the 387 children enrolled, 386 were included for safety analysis and 369 for efficacy evaluation. Four patients (1.0%) experienced mild adverse events that led to the discontinuation of vibegron, and all resolved promptly. Overall, 52.8% achieved a partial or complete response (CR) (≥50% reduction in wet nights), and 17.3% achieved a CR. The add-on group showed significantly greater improvements than the switch group (56.9% vs. 40.1% reduction, Pvs. 11%, P=0.006). Among the subgroups, the alarm addition subgroup showed the greatest reduction in wet nights (71.6%), while triple therapy also achieved high efficacy (61.6%). Conclusions: Vibegron is a safe and effective option for pediatric patients with TR-NE. Add-on strategies—particularly triple therapy—were more effective than monotherapy switching, strengthening the incorporation of vibegron as part of multimodal treatment strategies. Given the retrospective nature of the study, prospective randomized trials are warranted to confirm these findings and optimize the treatment protocols.
- Open Access
- 29 August 2025
- Published by Elsevier in Medical Reports
- Vol. 14
Late-onset afebrile neonatal bacteremia due to nontypeable Haemophilus influenzae: A case report
- 29 August 2025
- Published by Elsevier in Medical Reports
- Vol. 14
Open AccessLate-onset afebrile neonatal bacteremia due to nontypeable Haemophilus influenzae: A case report
- Open Access
- 1 August 2025
- Published by AME Publishing Company in Translational Pediatrics
- Vol. 14 (8) , 2042-2046
Arthritis associated with Kawasaki disease after initial combination therapy with cyclosporine: a case report
Background: Since the 2020 revision of the Kawasaki disease (KD) treatment guidelines, there have been few reports of reactive arthritis secondary to treatment-resistant KD. This study reports a case of KD that required initial treatment with cyclosporine A (CyA) followed by additional infliximab (IFX) and secondary to reactive arthritis. Case Description: A 5-year-old boy met diagnostic criteria for KD on day 5 of fever and had an intravenous immunoglobulin (IVIG) refractory predictive score of 8 (≥5) was administered ulinastatin, IFX, and three IVIG doses in combination with CyA. His fever resolved on day 9. Subsequently, acetylsalicylic acid was changed to flurbiprofen and then to dipyridamole due to suspicion of a drug rash. Fever and pain appeared in ankle joints and right hip joint on day 18 of illness. Prednisolone (PSL) was started on day 23 of illness for reactive arthritis associated with KD, which improved the joint pain. No recurrence of joint symptoms or coronary artery lesions was observed after tapering off of PSL. Conclusions: Based on the evaluation at the start of treatment, although CyA is initially administered in potential IVIG-resistant patients, attention must be paid to secondary reactive arthritis if the patient becomes resistant to treatment and requires IFX treatment.
- 1 August 2025
- Published by AME Publishing Company in Translational Pediatrics
- Vol. 14 (8) , 2042-2046
Open AccessArthritis associated with Kawasaki disease after initial combination therapy with cyclosporine: a case report
Background: Since the 2020 revision of the Kawasaki disease (KD) treatment guidelines, there have been few reports of reactive arthritis secondary to treatment-resistant KD. This study reports a case of KD that required initial treatment with cyclosporine A (CyA) followed by additional infliximab (IFX) and secondary to reactive arthritis. Case Description: A 5-year-old boy met diagnostic criteria for KD on day 5 of fever and had an intravenous immunoglobulin (IVIG) refractory predictive score of 8 (≥5) was administered ulinastatin, IFX, and three IVIG doses in combination with CyA. His fever resolved on day 9. Subsequently, acetylsalicylic acid was changed to flurbiprofen and then to dipyridamole due to suspicion of a drug rash. Fever and pain appeared in ankle joints and right hip joint on day 18 of illness. Prednisolone (PSL) was started on day 23 of illness for reactive arthritis associated with KD, which improved the joint pain. No recurrence of joint symptoms or coronary artery lesions was observed after tapering off of PSL. Conclusions: Based on the evaluation at the start of treatment, although CyA is initially administered in potential IVIG-resistant patients, attention must be paid to secondary reactive arthritis if the patient becomes resistant to treatment and requires IFX treatment.
- 1 January 2025
- Published by Wiley in Pediatrics International
- Vol. 67 (1) , e70204
Factors influencing the efficacy and self‐discontinuation of alarm therapy for Japanese patients with nocturnal enuresis
Background: Alarm therapy is the recommended first‐line treatment for nocturnal enuresis (NE). This study aimed to investigate the effectiveness of alarm monotherapy, identify predictors of treatment success, and examine factors contributing to self‐discontinuation in Japanese patients with NE. Methods: We retrospectively analyzed the treatment course of 112 patients with NE who received alarm monotherapy between January 2017 and September 2024. The primary outcome was the predictors of treatment effectiveness, and the secondary outcome was factors contributing to self‐discontinuation of alarm therapy. Results: At 3 months after initiating alarm monotherapy, treatment was effective in 49 patients (≥50% reduction in NE), while 41 showed poor response (p = 0.006), developmental disabilities ( p = 0.004), no prior NE treatment ( p = 0.011), and ineffective treatment at 3 and 6 months ( p = 0.001 and 0.045, respectively). Conclusions: Alarm monotherapy can be recommended for any patient as no factors predicting effectiveness were identified. However, patients with no prior treatment, DUI, neurodevelopmental disorders, or ineffective alarm therapy may struggle to continue treatment with alarm monotherapy.
- 1 January 2025
- Published by Wiley in Pediatrics International
- Vol. 67 (1) , e70204
Factors influencing the efficacy and self‐discontinuation of alarm therapy for Japanese patients with nocturnal enuresis
Background: Alarm therapy is the recommended first‐line treatment for nocturnal enuresis (NE). This study aimed to investigate the effectiveness of alarm monotherapy, identify predictors of treatment success, and examine factors contributing to self‐discontinuation in Japanese patients with NE. Methods: We retrospectively analyzed the treatment course of 112 patients with NE who received alarm monotherapy between January 2017 and September 2024. The primary outcome was the predictors of treatment effectiveness, and the secondary outcome was factors contributing to self‐discontinuation of alarm therapy. Results: At 3 months after initiating alarm monotherapy, treatment was effective in 49 patients (≥50% reduction in NE), while 41 showed poor response (p = 0.006), developmental disabilities ( p = 0.004), no prior NE treatment ( p = 0.011), and ineffective treatment at 3 and 6 months ( p = 0.001 and 0.045, respectively). Conclusions: Alarm monotherapy can be recommended for any patient as no factors predicting effectiveness were identified. However, patients with no prior treatment, DUI, neurodevelopmental disorders, or ineffective alarm therapy may struggle to continue treatment with alarm monotherapy.
- Open Access
Renoprotective effects of coenzyme Q10 supplementation in patients with chronic kidney disease: a protocol for a systematic review
Introduction Coenzyme Q10 (CoQ10) is a fat-soluble vitamin-like quinone. The plasma levels of CoQ10 are reduced in patients with chronic kidney disease (CKD). CoQ10 supplementation can improve mitochondrial function and decrease oxidative stress in these patients. This systematic review will assess the renoprotective effects of CoQ10 supplementation in patients with CKD. Methods and analysis We will include the following studies: (1) randomised-controlled trials, (2) participants with CKD and (3) participants treated with CoQ10 as an intervention. The systematic review protocol was prepared in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols. MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials and International Clinical Trials Register databases will be searched for articles without language restrictions in December 2024. The authors will be divided into two groups. Two independent authors will screen the titles and abstracts of all reports extracted via an electronic search. After the initial screening, the authors will independently review the full-text articles and perform a directed content analysis of the extracted data. For outcomes measured using continuous scales of measurement, we will adopt standardised mean differences as the effect measures. We will pool the data using the random‐effects model. Ethics and dissemination No human participants will be involved in the study. On completion of the analysis, the manuscript will be prepared for publication in a peer-reviewed journal. PROSPERO registration number CRD42021241085.
Open AccessRenoprotective effects of coenzyme Q10 supplementation in patients with chronic kidney disease: a protocol for a systematic review
Introduction Coenzyme Q10 (CoQ10) is a fat-soluble vitamin-like quinone. The plasma levels of CoQ10 are reduced in patients with chronic kidney disease (CKD). CoQ10 supplementation can improve mitochondrial function and decrease oxidative stress in these patients. This systematic review will assess the renoprotective effects of CoQ10 supplementation in patients with CKD. Methods and analysis We will include the following studies: (1) randomised-controlled trials, (2) participants with CKD and (3) participants treated with CoQ10 as an intervention. The systematic review protocol was prepared in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols. MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials and International Clinical Trials Register databases will be searched for articles without language restrictions in December 2024. The authors will be divided into two groups. Two independent authors will screen the titles and abstracts of all reports extracted via an electronic search. After the initial screening, the authors will independently review the full-text articles and perform a directed content analysis of the extracted data. For outcomes measured using continuous scales of measurement, we will adopt standardised mean differences as the effect measures. We will pool the data using the random‐effects model. Ethics and dissemination No human participants will be involved in the study. On completion of the analysis, the manuscript will be prepared for publication in a peer-reviewed journal. PROSPERO registration number CRD42021241085.